A citation-based method for searching scientific literature

Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
Times Cited: 4







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
Tao Bai, Pengxu Lei, Hao Zhou, Ruopeng Liang, Rongtao Zhu, Weijie Wang, Lin Zhou, Yuling Sun. J Cell Mol Med 2019
47
25

Neuroprotective Effects of the Anti-cancer Drug Lapatinib Against Epileptic Seizures via Suppressing Glutathione Peroxidase 4-Dependent Ferroptosis.
Ji-Ning Jia, Xi-Xi Yin, Qin Li, Qi-Wen Guan, Nan Yang, Kang-Ni Chen, Hong-Hao Zhou, Xiao-Yuan Mao. Front Pharmacol 2020
7
25

Emerging mechanisms and applications of ferroptosis in the treatment of resistant cancers.
Bowen Li, Liang Yang, Xueqiang Peng, Qin Fan, Shibo Wei, Shuo Yang, Xinyu Li, Hongyuan Jin, Bo Wu, Mingyao Huang,[...]. Biomed Pharmacother 2020
11
25

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.
J Remon, C E Steuer, S S Ramalingam, E Felip. Ann Oncol 2018
51
25


Global Epidemiology of Lung Cancer.
Julie A Barta, Charles A Powell, Juan P Wisnivesky. Ann Glob Health 2019
365
25

Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin.
Xuefei Zhang, Shiyao Sui, Lingling Wang, Haixia Li, Lei Zhang, Shouping Xu, Xiulan Zheng. J Cell Physiol 2020
63
25

Translational regulation of GPx-1 and GPx-4 by the mTOR pathway.
Emily N Reinke, Dede N Ekoue, Soumen Bera, Nadim Mahmud, Alan M Diamond. PLoS One 2014
11
25

Role of GPX4 in ferroptosis and its pharmacological implication.
Tobias M Seibt, Bettina Proneth, Marcus Conrad. Free Radic Biol Med 2019
213
25

Cancer, Oxidative Stress, and Metastasis.
Jennifer G Gill, Elena Piskounova, Sean J Morrison. Cold Spring Harb Symp Quant Biol 2016
114
25

DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo.
Shunnan Yao, Jianpin Ye, Mengqi Yin, Rui Yu. Cancer Lett 2020
14
25

Lapatinib.
Minna Voigtlaender, Tanja Schneider-Merck, Martin Trepel. Recent Results Cancer Res 2018
33
25

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Sanne C F A Huijberts, Robin M J M van Geel, Emilie M J van Brummelen, Frans L Opdam, Serena Marchetti, Neeltje Steeghs, Saskia Pulleman, Bas Thijssen, Hilde Rosing, Kim Monkhorst,[...]. Cancer Chemother Pharmacol 2020
11
25


Anti-tumor effects of Atractylenolide I on bladder cancer cells.
Rui Yu, Bi-Xia Yu, Jun-Feng Chen, Xiu-Yi Lv, Ze-Jun Yan, Yue Cheng, Qi Ma. J Exp Clin Cancer Res 2016
51
25

Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease.
Brent R Stockwell, José Pedro Friedmann Angeli, Hülya Bayir, Ashley I Bush, Marcus Conrad, Scott J Dixon, Simone Fulda, Sergio Gascón, Stavroula K Hatzios, Valerian E Kagan,[...]. Cell 2017
25


mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation.
Yilei Zhang, Robert V Swanda, Litong Nie, Xiaoguang Liu, Chao Wang, Hyemin Lee, Guang Lei, Chao Mao, Pranavi Koppula, Weijie Cheng,[...]. Nat Commun 2021
42
25

New driver mutations in non-small-cell lung cancer.
William Pao, Nicolas Girard. Lancet Oncol 2011
808
25


Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
Sara Redaelli, Monica Ceccon, Marina Zappa, Geeta G Sharma, Cristina Mastini, Mario Mauri, Marion Nigoghossian, Luca Massimino, Nicoletta Cordani, Francesca Farina,[...]. Cancer Res 2018
36
25


Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.
M Ceccon, L Mologni, G Giudici, R Piazza, A Pirola, D Fontana, C Gambacorti-Passerini. Mol Cancer Res 2015
44
25


Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.
Avedis Torossian, Nicolas Broin, Julie Frentzel, Camille Daugrois, Sarah Gandarillas, Talal Al Saati, Laurence Lamant, Pierre Brousset, Sylvie Giuriato, Estelle Espinos. Haematologica 2019
13
25

Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
Eric J Lowe, Anne F Reilly, Megan S Lim, Thomas G Gross, Lauren Saguilig, Donald A Barkauskas, Rui Wu, Sarah Alexander, Catherine M Bollard. Blood 2021
12
25

Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
S Redaelli, F Boschelli, P Perini, A Pirola, M Viltadi, C Gambacorti-Passerini. Leukemia 2010
14
25

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.
Elisa Sala, Luca Mologni, Silvia Truffa, Carlo Gaetano, Gideon E Bollag, Carlo Gambacorti-Passerini. Mol Cancer Res 2008
148
25

NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.
Chiara Ambrogio, Cinzia Martinengo, Claudia Voena, Fabrizio Tondat, Ludovica Riera, Paola Francia di Celle, Giorgio Inghirami, Roberto Chiarle. Cancer Res 2009
66
25

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
Gorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos, Asmin Tulpule, Saurabh Asthana, Collin M Blakely, Ross A Okimoto, Luping Lin, Dana S Neel, Amit Sabnis,[...]. Nat Med 2015
169
25


Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy.
Meghan Leary, Sarah Heerboth, Karolina Lapinska, Sibaji Sarkar. Cancers (Basel) 2018
63
25

Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Monica Ceccon, Luca Mologni, William Bisson, Leonardo Scapozza, Carlo Gambacorti-Passerini. Mol Cancer Res 2013
65
25

Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.
Melanie R Hassler, Aleksandra Klisaroska, Karoline Kollmann, Irene Steiner, Martin Bilban, Ana-Iris Schiefer, Veronika Sexl, Gerda Egger. Biochimie 2012
38
25

NPM-ALK expression levels identify two distinct subtypes of paediatric anaplastic large cell lymphoma.
E Pomari, G Basso, S Bresolin, M Pillon, E Carraro, E S d'Amore, G Viola, C Frasson, K Basso, P Bonvini,[...]. Leukemia 2017
6
25

IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK.
Qian Zhang, Hong Yi Wang, Xiaobin Liu, Gauri Bhutani, Kanchan Kantekure, Mariusz Wasik. Proc Natl Acad Sci U S A 2011
36
25


Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
601
25

The anaplastic lymphoma kinase in the pathogenesis of cancer.
Roberto Chiarle, Claudia Voena, Chiara Ambrogio, Roberto Piva, Giorgio Inghirami. Nat Rev Cancer 2008
577
25

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Nathan F Moore, Anna M Azarova, Namrata Bhatnagar, Kenneth N Ross, Lauren E Drake, Stacey Frumm, Qinsong S Liu, Amanda L Christie, Takaomi Sanda, Louis Chesler,[...]. Oncotarget 2014
56
25

Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.
Rocco Piazza, Vera Magistroni, Angela Mogavero, Federica Andreoni, Chiara Ambrogio, Roberto Chiarle, Luca Mologni, Petra S Bachmann, Richard B Lock, Paola Collini,[...]. Neoplasia 2013
37
25

p21(Waf1/Cip1/Sdi1) mediates shear stress-dependent antiapoptotic function.
Stefania Mattiussi, Paolo Turrini, Lucia Testolin, Fabio Martelli, Germana Zaccagnini, Antonella Mangoni, Laura M Barlucchi, Annalisa Antonini, Barbara Illi, Corrado Cirielli,[...]. Cardiovasc Res 2004
21
25

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Farhad Ravandi, Susan M O'Brien, Jorge E Cortes, Deborah M Thomas, Rebecca Garris, Stefan Faderl, Jan A Burger, Michael E Rytting, Alessandra Ferrajoli, William G Wierda,[...]. Cancer 2015
122
25

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.
Carlo Gambacorti-Passerini, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin-Seok Ahn, Joseph T Beck, William Jeffrey Edenfield,[...]. Am J Hematol 2018
42
25

Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.
Matteo Menotti, Chiara Ambrogio, Taek-Chin Cheong, Chiara Pighi, Ines Mota, Seth H Cassel, Mara Compagno, Qi Wang, Riccardo Dall'Olio, Valerio G Minero,[...]. Nat Med 2019
30
25

Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.
Mi Ran Yun, Sun Min Lim, Seon-Kyu Kim, Hun Mi Choi, Kyoung-Ho Pyo, Seong Keun Kim, Ji Min Lee, You Won Lee, Jae Woo Choi, Hye Ryun Kim,[...]. Cancer Res 2018
15
25


Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.
Carlo Gambacorti Passerini, Francesca Farina, Alessandra Stasia, Sara Redaelli, Monica Ceccon, Luca Mologni, Cristina Messa, Luca Guerra, Giovanni Giudici, Elena Sala,[...]. J Natl Cancer Inst 2014
155
25

Induction of p16ink4a and p19ARF by TGFbeta1 contributes to growth arrest and senescence response in mouse keratinocytes.
Kinnimulki Vijayachandra, William Higgins, Jessica Lee, Adam Glick. Mol Carcinog 2009
46
25

Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells.
Luca Mologni, Stefania Brussolo, Monica Ceccon, Carlo Gambacorti-Passerini. PLoS One 2012
31
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.